American Journal of Epidemiology Advance Access originally published online on April 26, 2006
American Journal of Epidemiology 2006 163(11):1068-1069; doi:10.1093/aje/kwj157
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American Journal of Epidemiology Copyright © 2006 by the Johns Hopkins Bloomberg School of Public Health All rights reserved; printed in U.S.A.
Letter to the Editor |
FIVE AUTHORS REPLY
1 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
2 Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA
3 Medstar Research Institute, Hyattsville, MD
4 Department of Obstetrics and Gynecology, Albert Einstein School of Medicine, Bronx, NY
5 Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
(e-mail: rprentic@fhcrc.org)
| The first 10% of the full text of this article appears below. |
We thank Willett et al. (1
) for responding to our article (2
) on a potential bias in Nurses' Health Study findings on combined estrogen plus progestin postmenopausal hormone therapy and coronary heart disease. We suggested that the use of only a biennial snapshot of current hormone therapy use could have led to a downward bias in hazard ratio estimates from the Nurses' Health Study (3
), in view of the elevation in coronary heart disease risk in the first few years following hormone therapy initiation observed in the Women's